[Federal Register Volume 88, Number 95 (Wednesday, May 17, 2023)]
[Notices]
[Page 31510]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10499]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services is hereby
giving notice that the Advisory Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a meeting. The meeting will be open
to the public via webcast. The committee will discuss and vote on a
recommendation related to surge capacity for blood and blood products.
DATES: The meeting will take place on July 6-7, 2023 from approximately
10 a.m.-3 p.m. Eastern Time (ET) each day. Meeting times are tentative
and subject to change. The confirmed times and agenda items for the
meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2023-07-06/index.html when this information becomes available.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Tower Building, 1101 Wootton Parkway,
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-7608.
SUPPLEMENTARY INFORMATION: On the day of the meeting, please go to
https://www.hhs.gov/live/index.html to view the meeting. The public
will have an opportunity to present their views to the ACBTSA by
submitting a written public comment. Comments should be pertinent to
the meeting discussion. Persons who wish to provide written public
comment should review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2023-07-06/index.html and respond by midnight June 28, 2023, ET. Written public
comments will be accessible to the public on the ACBTSA web page prior
to the meeting.
Background and Authority: The ACBTSA is a discretionary Federal
advisory committee and is governed by the provisions of the Federal
Advisory Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C.
app), which sets forth standards for the formation and use of advisory
committees. The ACBTSA functions to provide advice to the Secretary
through the Assistant Secretary for Health on a range of policy issues
to include: (1) Identification of public health issues through
surveillance of blood and tissue safety issues with national survey and
data tools; (2) identification of public health issues that affect
availability of blood, blood products, and tissues; (3) broad public
health, ethical, and legal issues related to the safety of blood, blood
products, and tissues; (4) the impact of various economic factors
(e.g., product cost and supply) on safety and availability of blood,
blood products, and tissues; (5) risk communications related to blood
transfusion and tissue transplantation; and (6) identification of
infectious disease transmission issues for blood, organs, blood stem
cells and tissues. The Committee has met regularly since its
establishment in 1997.
Dated: May 2, 2023.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue
Safety and Availability, Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2023-10499 Filed 5-16-23; 8:45 am]
BILLING CODE 4150-28-P